RXi Pharmaceuticals Corp. (RXII) Tops Q2 EPS by 2c

RXi Pharmaceuticals Corp. (NASDAQ: RXII) reported Q2 EPS of ($0.23), $0.02 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $12 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on RXi Pharmaceuticals Corp. (RXII) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low
• Royal Unibrew reports higher interim first-half profit as margins improve